MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin

(2018) Stefan Zeuzem et al.   GASTROENTEROLOGY

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

(2012) Steven Harper et al.   ACS Medicinal Chemistry Letters

1231 SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV

(2011) S. Pol et al.   JOURNAL OF HEPATOLOGY

62 ACTIVITY OF DANOPREVIR PLUS LOW-DOSE RITONAVIR (DNV/R) IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (PEGIFNa-2A/RBV) IN PREVIOUS NULL RESPONDERS

(2011) R. Rouzier et al.   JOURNAL OF HEPATOLOGY

1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS

(2011) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

63 CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052

(2011) F. McPhee et al.   JOURNAL OF HEPATOLOGY

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

(2011) J.-P. Bronowicki et al.   JOURNAL OF HEPATOLOGY

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

(2011) J.C. Sullivan et al.   JOURNAL OF HEPATOLOGY

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

(2010) C. M. Lange et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

(2010) P. W. White et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hepatitis C virus replication cycle

(2010) Ralf Bartenschlager et al.   JOURNAL OF HEPATOLOGY

Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

(2010) John A. McCauley et al.   JOURNAL OF MEDICINAL CHEMISTRY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

New Insights into Structure and Replication of the Hepatitis C Virus and Clinical Implications

(2010) Marion Poenisch et al.   SEMINARS IN LIVER DISEASE

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

(2009) T.-I Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

(2009) N. J. Liverton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

(2008) S. S. Carroll et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

(2008) S. D. Seiwert et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

(2008) A. Y. M. Howe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350

(2008) Pierre Raboisson et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES

Molecular Modeling Based Approach to Potent P2−P4 Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease

(2008) Nigel J. Liverton et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

A transient cell-based phenotype assay for hepatitis C NS3/4A protease: Application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV

(2008) Steven W. Ludmerer et al.   JOURNAL OF VIROLOGICAL METHODS

A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3–4A protease at low enzyme concentrations

(2007) Shi-Shan Mao et al.   ANALYTICAL BIOCHEMISTRY